Goldman Sachs Group Inc. Takes $597,000 Position in Benitec Biopharma Limited $BNTC

Key Points

• Goldman Sachs acquired a new stake in Benitec Biopharma, purchasing 45,883 shares valued at approximately $597,000, reflecting a 0.17% ownership in the company.
• Several institutional investors have recently increased their holdings in Benitec Biopharma, contributing to a total institutional ownership of 52.19%.
• Despite the positive analyst ratings, Benitec Biopharma reported an earnings miss with a loss of ($0.42) EPS, falling short of the consensus estimate of ($0.24).

Goldman Sachs Group Inc. bought a new stake in Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,883 shares of the biotechnology company's stock, valued at approximately $597,000. Goldman Sachs Group Inc. owned 0.17% of Benitec Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of BNTC. Ameriprise Financial Inc. boosted its position in shares of Benitec Biopharma by 138.4% in the fourth quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after acquiring an additional 20,597 shares during the period. Northern Trust Corp boosted its position in shares of Benitec Biopharma by 54.2% in the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock valued at $482,000 after acquiring an additional 13,425 shares during the period. Informed Momentum Co LLC bought a new stake in shares of Benitec Biopharma in the first quarter valued at about $512,000. MYDA Advisors LLC boosted its position in shares of Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company's stock valued at $677,000 after acquiring an additional 2,000 shares during the period. Finally, GAMMA Investing LLC raised its stake in Benitec Biopharma by 1,104.3% in the first quarter. GAMMA Investing LLC now owns 77,605 shares of the biotechnology company's stock valued at $1,010,000 after purchasing an additional 71,161 shares in the last quarter. Institutional investors own 52.19% of the company's stock.

Benitec Biopharma Stock Up 6.6%

Shares of NASDAQ BNTC opened at $14.09 on Thursday. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01. The company has a market cap of $369.86 million, a price-to-earnings ratio of -9.58 and a beta of 0.43. Benitec Biopharma Limited has a 12 month low of $8.49 and a 12 month high of $17.15. The stock has a 50-day moving average price of $12.65 and a two-hundred day moving average price of $13.47.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.18). As a group, analysts forecast that Benitec Biopharma Limited will post -1.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BNTC. TD Cowen began coverage on Benitec Biopharma in a research note on Monday, July 7th. They issued a "buy" rating for the company. Oppenheimer reaffirmed an "outperform" rating and issued a $29.00 price target (down previously from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of "Buy" and an average price target of $24.80.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.